ESPR logo

Esperion Therapeutics (ESPR)

Profile

Full Name

Esperion Therapeutics, Inc.

Ticker Symbol

ESPR

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

June 26, 2013

Indexes

Not included

Website

http://www.esperion.com

Employees

304

Key Details

Price

$1.02(+6.25%)

Market cap

$201.81M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$332.31M(+185.66% YoY)

Annual EPS

-$0.28(+86.21% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.02
ESPR price is $1.02

30-Day Relative Volume

1.59
ESPR 30-day relative volume is 1.59

Price Performance

Price Most recent change

+6.25%
ESPR price was up +6.25% on Apr 11, 2025

Price YTD change

-53.64%
ESPR price is down -53.64% since January 1st

Price 1-year change

-55.84%
ESPR price is down -55.84% year-on-year

Price 3-year change

-81.82%
ESPR price is down -81.82% over the past 3 years

Price Range

Price All-time high

$120.96
ESPR price is currently -99.16% below its historical high of $120.96

Price 3-year low

$0.70
ESPR price is currently +45.71% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$201.81M
ESPR market capitalization is $201.81 million

Market cap 3-year change

-41.13%
ESPR market capitalization is down -41.13% over the past 3 years

Market cap All-time high

$2.59B
ESPR market capitalization is currently -92.21% below its historical high of $2.59 billion

Market cap sector rank

58.09%
ESPR market capitalization is higher than 58.09% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+5.32%
ESPR shares outstanding is up +5.32% year-on-year

Shares Outstanding 3-Year Change

+223.81%
ESPR shares outstanding is up +223.81% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.96
ESPR beta is 0.96

200-day SMA

$2.03
ESPR price is currently -49.81% below its 200-day simple moving average

50-day SMA

$1.61
ESPR price is currently -36.71% below its 50-day simple moving average

RSI

25.00
ESPR 14-day relative strength index is 25.00

Volume

1.59
ESPR 30-day relative volume is 1.59

ATR

$0.11
ESPR average true range is $0.11

10-day Historical Volatility

77.85%
ESPR 10-day historical volatility is 77.85%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$332.31M
ESPR annual revenue is $332.31 million

Revenue Analysts estimate

$347.17M
ESPR annual revenue is currently -4.28% lower than the consensus analysts' forecast

Revenue 1-year change

+185.66%
ESPR annual revenue is up +185.66% year-on-year

Revenue Sector rank

69.76%
ESPR annual revenue is higher than 69.76% of companies in Healthcare sector

EPS

EPS

-$0.28
ESPR annual earnings per share is -$0.28

EPS Analysts estimate

-$0.03
ESPR annual earnings per share is currently +740.84% higher than the consensus analysts' forecast

EPS 1-year change

+86.21%
ESPR annual earnings per share is up +86.21% year-on-year

EPS Sector rank

75.47%
ESPR annual earnings per share is higher than 75.47% of companies in Healthcare sector

Profit

Gross profit

$263.71M
ESPR annual gross profit is $263.71 million

Gross margin

79.36%
ESPR annual gross profit margin is 79.36%

Operating profit

$54.40M
ESPR annual operating income is $54.40 million

Operating margin

16.37%
ESPR annual operating profit margin is 16.37%

Net income

-$51.74M
ESPR annual net profit is -$51.74 million

Net margin

-15.57%
ESPR annual net profit margin is -15.57%

Expenses

Total expenses

$277.91M
ESPR annual total expenses is $277.91 million

Operating expenses

$209.31M
ESPR annual total operating expenses is $209.31 million

Cost of goods sold

$68.60M
ESPR annual cost of goods sold is $68.60 million

Selling, general & administrative expenses

$163.07M
ESPR annual SGA is $163.07 million

Depreciation and amortization

$63.00K
ESPR annual depreciation & amortization is $63.00 thousand

Interest expense

$59.25M
ESPR annual interest expense is $59.25 million

Income tax

-
ESPR annual income tax value is unknown

EBIT & EBITDA

EBIT

$7.51M
ESPR annual earnings before interest & taxes is $7.51 million

EBITDA

$7.51M
ESPR annual EBITDA is $7.51 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$343.82M
ESPR annual total assets is $343.82 million

Non current assets

$5.82M
ESPR annual long term assets is $5.82 million

Current assets

$144.76M
ESPR annual total current assets is $144.76 million

Cash and cash equivalents

$144.76M
ESPR annual cash & cash equivalents is $144.76 million

Accounts receivable

$80.14M
ESPR annual accounts receivable is $80.14 million

Inventory

$94.49M
ESPR annual inventory is $94.49 million

Liabilities

Total liabilities

$732.54M
ESPR annual total liabilities is $732.54 million

Long term liabilities

$486.31M
ESPR annual total long term liabilities is $486.31 million

Current liabilities

$246.23M
ESPR annual total current liabilities is $246.23 million

Accounts payable

$51.65M
ESPR annual accounts payable is $51.65 million

Debt

Total debt

$297.60M
ESPR annual total debt is $297.60 million

Total debt 1-year change

+11.81%
ESPR annual total debt is up +11.81% year-on-year

Long term debt

$240.29M
ESPR annual long term debt is $240.29 million

Short term debt

$57.32M
ESPR annual short term debt is $57.32 million

Equity & Capital

Shareholders equity

-$388.72M
ESPR annual stockholders equity is -$388.72 million

Book value

-$1.60B
ESPR annual book value is -$1.60 billion

Retained earnings

-$1.60B
ESPR annual retained earnings is -$1.60 billion

Working capital

$91.77M
ESPR annual working capital is $91.77 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$23.65M
ESPR annual cash flow from operations is -$23.65 million

Cash from operations 1-year change

+82.54%
ESPR annual cash flow from operations is up +82.54% year-on-year

Cash from investing

-$317.00K
ESPR annual cash flow from investing activities is -$317.00 thousand

Cash from investing 1-year change

-100.75%
ESPR annual cash flow from investing activities is down -100.75% year-on-year

Cash from financing

$86.48M
ESPR annual cash flow from financing activities is $86.48 million

Cash from financing 1-year change

+71.39%
ESPR annual cash flow from financing activities is up +71.39% year-on-year

CAPEX

CAPEX

$317.00K
ESPR annual capital expenditures is $317.00 thousand

CAPEX 1-year change

-
ESPR annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$23.97M
ESPR annual free cash flow is -$23.97 million

Free cash flow 1-year change

+82.31%
ESPR annual free cash flow is up +82.31% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

79.36%
ESPR annual gross profit margin is 79.36%

Operating margin

16.37%
ESPR annual operating profit margin is 16.37%

Net margin

-15.57%
ESPR annual net profit margin is -15.57%

ROA & ROE

ROA

-18.83%
ESPR annual return on assets is -18.83%

ROE

13.31%
ESPR annual return on equity is 13.31%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
ESPR price to earnings ratio value is unknown

PE ratio Sector rank

-
ESPR price to earnings ratio is unknown

PB Ratio

PB ratio

-0.52
ESPR price to book ratio is -0.52

PB ratio Sector rank

10.28%
ESPR price to book ratio is higher than 10.28% of companies in Healthcare sector

PS Ratio

PS ratio

0.61
ESPR price to sales ratio is 0.61

PS ratio Sector rank

19.74%
ESPR price to sales ratio is higher than 19.74% of companies in Healthcare sector

Enterprise value

Enterprise value

$354.65M
ESPR enterprise value is $354.65 million

Enterprise value Sector rank

65.48%
ESPR enterprise value is higher than 65.48% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

47.02
ESPR EV/EBITDA is 47.02

EV/EBITDA Sector rank

97.13%
ESPR EV/EBITDA is higher than 97.13% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.37
ESPR annual current ratio is 1.37

Quick ratio

0.20
ESPR annual quick ratio is 0.20

Leverage

Debt to equity

0.00
ESPR annual debt to equity ratio is 0.00

Interest coverage ratio

0.13
ESPR annual interest coverage ratio is 0.13

Risk & Stability

Piotroski F-Score

4
ESPR piotroski f-score is 4

Altman Z-Score

-5.00
ESPR altman z-score is -5.00

Analyst ratings

Recent major analysts updates

Apr 8, 25 Needham
Buy
Mar 20, 25 HC Wainwright & Co.
Buy
Mar 5, 25 Citizens Capital Markets
Market Outperform
Mar 4, 25 HC Wainwright & Co.
Buy
Feb 11, 25 JMP Securities
Market Outperform
Feb 11, 25 HC Wainwright & Co.
Buy
Jan 23, 25 JMP Securities
Market Outperform
Jan 23, 25 HC Wainwright & Co.
Buy
Jan 22, 25 HC Wainwright & Co.
Buy
Jan 10, 25 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

QTRX logo
Quanterix (QTRX)
OCGN logo
Ocugen (OCGN)
CRVS logo
Corvus Pharmaceuticals (CRVS)
DRUG logo
Bright Minds Biosciences (DRUG)
DBVT logo
DBV Technologies SA (DBVT)
enGene Holdings (ENGN)
CDTX logo
Cidara Therapeutics (CDTX)
TVGN logo
Tevogen Bio Holdings (TVGN)
PDEX logo
Pro-Dex (PDEX)
  • What is the ticker symbol for Esperion Therapeutics?
  • Does Esperion Therapeutics pay dividends?
  • What sector is Esperion Therapeutics in?
  • What industry is Esperion Therapeutics in?
  • What country is Esperion Therapeutics based in?
  • When did Esperion Therapeutics go public?
  • Is Esperion Therapeutics in the S&P 500?
  • Is Esperion Therapeutics in the NASDAQ 100?
  • Is Esperion Therapeutics in the Dow Jones?
  • When was Esperion Therapeutics's last earnings report?
  • When does Esperion Therapeutics report earnings?
  • Should I buy Esperion Therapeutics stock now?

What is the ticker symbol for Esperion Therapeutics?

The ticker symbol for Esperion Therapeutics is NASDAQ:ESPR

Does Esperion Therapeutics pay dividends?

No, Esperion Therapeutics does not pay dividends

What sector is Esperion Therapeutics in?

Esperion Therapeutics is in the Healthcare sector

What industry is Esperion Therapeutics in?

Esperion Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Esperion Therapeutics based in?

Esperion Therapeutics is headquartered in United States

When did Esperion Therapeutics go public?

Esperion Therapeutics's initial public offering (IPO) was on June 26, 2013

Is Esperion Therapeutics in the S&P 500?

No, Esperion Therapeutics is not included in the S&P 500 index

Is Esperion Therapeutics in the NASDAQ 100?

No, Esperion Therapeutics is not included in the NASDAQ 100 index

Is Esperion Therapeutics in the Dow Jones?

No, Esperion Therapeutics is not included in the Dow Jones index

When was Esperion Therapeutics's last earnings report?

Esperion Therapeutics's most recent earnings report was on Mar 4, 2025

When does Esperion Therapeutics report earnings?

The next expected earnings date for Esperion Therapeutics is May 7, 2025

Should I buy Esperion Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page